Evidence map›Paper›PMID 41516330›Full record

ArticleInternational journal of molecular sciences2026

Impact of Brodalumab on Serum Levels of IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α in Patients with Psoriasis Who Failed Treatment with TNF-α Inhibitors.

Lucia Medjedovic, Admir Vižlin, Ylva Andersch Björkman, Anna-Maj Albertsson, Sukanya Raghavan, Martin Gillstedt, Amra Osmancevic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucia MedjedovicDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.
Admir VižlinDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.
Ylva Andersch BjörkmanDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.
Anna-Maj AlbertssonDepartment of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Region Västra Götaland, 413 45 Gothenburg, Sweden.
Sukanya RaghavanDepartment of Clinical Immunology and Transfusion Medicine, Sahlgrenska University Hospital, Region Västra Götaland, 413 45 Gothenburg, Sweden.
Martin GillstedtDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.ORCID 0000-0001-5033-5421
Amra OsmancevicDepartment of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden.

Funding

Leo Pharma (Denmark) SAHL1011
6 · The paper itself

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts patients' quality of life. While TNF-α inhibitors are frequently used to treat moderate-to-severe cases, not all patients respond adequately. Brodalumab, a monoclonal antibody targeting the IL-17 receptor A, has emerged as an alternative for individuals unresponsive to prior therapies. This prospective study investigated the effects of brodalumab on serum cytokine levels-specifically IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α-and their correlation with disease severity as assessed by Psoriasis Area and Severity Index (PASI). Eighteen patients with moderate-to-severe psoriasis who were unresponsive to TNF-α inhibitors received brodalumab for 12 weeks. Cytokine concentrations were measured at baseline and week 12 using an automated immunoassay (ELLA), and clinical outcomes were evaluated using PASI. The results showed a significant increase in IL-17A levels, while changes in IL-6, IFN-α, IFN-γ, and TNF-α did not reach statistical significance. No significant correlations were found between changes in cytokine levels and PASI improvement. However, the small number of available serum samples at week 12 (

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedCytokinesPsoriasisTumor Necrosis Factor-alphaAdultFemaleHumansInterferon-alphaInterferon-gammaInterleukin-17Interleukin-6MaleMiddle AgedProspective StudiesSeverity of Illness IndexAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedbrodalumabCytokinesInterferon-alphaInterferon-gammaInterleukin-17Interleukin-6Tumor Necrosis Factor-alphabrodalumabcytokinesIL-17 inhibitorpsoriasisTNF-α inhibitor

Identifiers

PMID41516330
PMCPMC12786795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.